Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis

Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis

For chronic hepatitis B (CHB), alanine aminotransferase (ALT) ≥2 × upper limit of normal (ULN) is often used as a major criteria to initiate treatment in absence of cirrhosis, though patients with lower ALT may not be free from future risk of hepatocellular carcinoma (HCC). We aimed to examine the e...

Full description

Bibliographic Details
Main Authors: Hoang, Joseph K., Yang, Hwai-I, Le, An, Nguyen, Nghia H., Lin, Derek, Vu, Vinh D., Chaung, Kevin, Nguyen, Vincent, Trinh, Huy N., Li, Jiayi, Zhang, Jian Q., Chen, Chien-Jen, Nguyen, Mindie H.
Format: Online
Language:English
Published: Wolters Kluwer Health 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979821/
id pubmed-4979821
recordtype oai_dc
spelling pubmed-49798212016-08-18 Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis Hoang, Joseph K. Yang, Hwai-I Le, An Nguyen, Nghia H. Lin, Derek Vu, Vinh D. Chaung, Kevin Nguyen, Vincent Trinh, Huy N. Li, Jiayi Zhang, Jian Q. Chen, Chien-Jen Nguyen, Mindie H. 4500 For chronic hepatitis B (CHB), alanine aminotransferase (ALT) ≥2 × upper limit of normal (ULN) is often used as a major criteria to initiate treatment in absence of cirrhosis, though patients with lower ALT may not be free from future risk of hepatocellular carcinoma (HCC). We aimed to examine the effect of antiviral therapy on HCC incidence based on ALT levels. Wolters Kluwer Health 2016-08-07 /pmc/articles/PMC4979821/ /pubmed/27495067 http://dx.doi.org/10.1097/MD.0000000000004433 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Hoang, Joseph K.
Yang, Hwai-I
Le, An
Nguyen, Nghia H.
Lin, Derek
Vu, Vinh D.
Chaung, Kevin
Nguyen, Vincent
Trinh, Huy N.
Li, Jiayi
Zhang, Jian Q.
Chen, Chien-Jen
Nguyen, Mindie H.
spellingShingle Hoang, Joseph K.
Yang, Hwai-I
Le, An
Nguyen, Nghia H.
Lin, Derek
Vu, Vinh D.
Chaung, Kevin
Nguyen, Vincent
Trinh, Huy N.
Li, Jiayi
Zhang, Jian Q.
Chen, Chien-Jen
Nguyen, Mindie H.
Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
author_facet Hoang, Joseph K.
Yang, Hwai-I
Le, An
Nguyen, Nghia H.
Lin, Derek
Vu, Vinh D.
Chaung, Kevin
Nguyen, Vincent
Trinh, Huy N.
Li, Jiayi
Zhang, Jian Q.
Chen, Chien-Jen
Nguyen, Mindie H.
author_sort Hoang, Joseph K.
title Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
title_short Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
title_full Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
title_fullStr Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
title_full_unstemmed Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
title_sort lower liver cancer risk with antiviral therapy in chronic hepatitis b patients with normal to minimally elevated alt and no cirrhosis
description For chronic hepatitis B (CHB), alanine aminotransferase (ALT) ≥2 × upper limit of normal (ULN) is often used as a major criteria to initiate treatment in absence of cirrhosis, though patients with lower ALT may not be free from future risk of hepatocellular carcinoma (HCC). We aimed to examine the effect of antiviral therapy on HCC incidence based on ALT levels.
publisher Wolters Kluwer Health
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979821/
_version_ 1613625038648377344

Similar Items